Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
SALBUTAMOL INHALATION HAS NO EFFECT ON MYOCARDIAL-ISCHEMIA, ARRHYTHMIAS AND HEART-RATE-VARIABILITY IN PATIENTS WITH CORONARY-ARTERY DISEASEPLUS ASTHMA OR CHRONIC OBSTRUCTIVE PULMONARY-DISEASE
Autore:
ROSSINEN J; PARTANEN J; STENIUSAARNIALA B; NIEMINEN MS;
Indirizzi:
UNIV HELSINKI,CENT HOSP,DEPT MED,DIV CARDIOL,HAARTMANINKATU 4 FIN-00290 HELSINKI FINLAND
Titolo Testata:
Journal of internal medicine
fascicolo: 5, volume: 243, anno: 1998,
pagine: 361 - 366
SICI:
0954-6820(1998)243:5<361:SIHNEO>2.0.ZU;2-W
Fonte:
ISI
Lingua:
ENG
Soggetto:
BRONCHODILATORS; TERBUTALINE; MORTALITY;
Keywords:
ASTHMA; CHRONIC OBSTRUCTIVE PULMONARY DISEASE; CORONARY ARTERY DISEASE; HEART RATE VARIABILITY; MYOCARDIAL ISCHEMIA; SALBUTAMOL;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Citazioni:
24
Recensione:
Indirizzi per estratti:
Citazione:
J. Rossinen et al., "SALBUTAMOL INHALATION HAS NO EFFECT ON MYOCARDIAL-ISCHEMIA, ARRHYTHMIAS AND HEART-RATE-VARIABILITY IN PATIENTS WITH CORONARY-ARTERY DISEASEPLUS ASTHMA OR CHRONIC OBSTRUCTIVE PULMONARY-DISEASE", Journal of internal medicine, 243(5), 1998, pp. 361-366

Abstract

Objectives. Inhaled beta-2 agonists raise heart rate, systolic blood pressure and contractility, all of which cause an increase in oxygen consumption of the heart. We performed a study on the influence of inhaled salbutamol on myocardial ischaemia, rhythm, and heart rate variability as assessed by Holter monitoring of 24 patients with coronary artery disease (CAD) and clinically stable asthma or chronic obstructive pulmonary disease (COPD). Design. In hospital the patients received 0.2 mg (hour 1), 0.4 mg (hour 6), 0.8 mg (hour 13) of salbutamol with a metered-dose inhaler and a spacer, and 5 mg (hour 25) with a nebulizer; symptoms, peak expiratory flow (PEF), 30-h Holter monitoring, and blood pressure (BP) were recorded. The study parameters were compared for the hour preceding and following each dose of salbutamol. Results, No cardiac symptoms were associated with salbutamol inhalation. PEF increased after all doses (P < 0.005). A dose of 0.2 mg salbutamol induced no changes in heart rate, whereas dose of 0.4 mg increased heart rate from a mean of 75 +/- 13 to 79 +/- 14 beats min(-1) (P < 0.005), anda dose of 0.8 mg from 76 +/- 14 to 78 +/- 15 beats min(-1) (P < 0.05). No changes in systolic BP appeared after any dose of salbutamol. Thediastolic BP was lowered after 0.8 mg of salbutamol from 86 +/- 12 to82 +/- 10 mmHg (P < 0.05). The 5 mg of nebulized drug provoked no significant changes in heart rate or BP. Myocardial ischaemia, heart ratevariability and ventricular arrhythmias remained unaltered with all doses. Conclusions. The commonly used doses of inhaled or nebulized salbutamol induced no acute myocardial ischaemia, arrhythmias or changes in heart rate variability in patients with CAD and clinically stable asthma or COPD.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 10/07/20 alle ore 12:49:43